Whole-brain Radiotherapy With or Without a Simultaneous Integrated Boost for Treatment of Brain Metastases.

Area of Science:

• Radiation Oncology
• Neuro-oncology
• Clinical Cancer Research

Background:

• Whole-brain radiotherapy (WBRT) is a standard treatment for brain metastases.
• Stereotactic radiotherapy and WBRT with simultaneous integrated boost (WBRT+SIB) are emerging alternatives.
• This study evaluates WBRT+SIB against WBRT alone for unresected brain metastases.

Purpose of the Study:

• To compare the efficacy of WBRT+SIB versus WBRT alone in managing brain metastases.
• To assess the impact of WBRT+SIB on intracerebral control and overall survival.
• To identify patient subgroups that may benefit from WBRT+SIB.

Main Methods:

• A comparative study involving 103 patients treated with WBRT+SIB and 275 patients treated with WBRT alone.
• Intracerebral control (IC) and overall survival (OS) were the primary endpoints.
• Multivariate analyses were performed to identify significant prognostic factors.

Main Results:

• WBRT+SIB was significantly associated with improved IC (p=0.041).
• Karnofsky performance score (KPS) >70, 1-3 brain metastases, favorable tumor type, and absence of extracranial metastases were associated with better OS.
• No significant difference in OS was observed between WBRT and WBRT+SIB groups.

Conclusions:

• WBRT+SIB demonstrates superior intracerebral control compared to WBRT alone for brain metastases.
• Overall survival is comparable between the two treatment modalities.
• WBRT+SIB may be beneficial for selected patients at high risk of intracerebral recurrence.